Study program of the oral FXIa inhibitor BAY 2433334 – Non-cardioembolic Stroke study
This study will assess the dose-response of BAY 2433334 in order to determine the dose that is efficacious and safe and that can be used in a Phase 3 study in the same indication. Current guidelines recommend antiplatelet therapy for patients after a non-cardioembolic stroke / transient ischemic attack (TIA).
The inhibition of FXIa on top of antiplatelet therapy is expected to lead to a benefit regarding secondary prevention of stroke combined with no or only minimal increase in bleeding and especially no increase in major bleeding.
Randomized, placebo-controlled, double-blind, dose-finding Phase 2 study. Parallel group treatment study with four arms that is participant and investigator blinded.